治疗2型糖尿病新靶点——糖原合成酶激酶3及其抑制剂的研究进展

Advances inresearch on glycogen synthase kinase-3 inhibitor as a novel target for anti-type 2 diabetes mellitus drugs

糖原合成酶激酶3(GSK-3)是一种表达于多种组织的多功能丝氨酸/苏氨酸类蛋白激酶,涉及体内多种细胞信号转导途径。更多研究证实,GSK-3的活性异常在T2DM的发生发展中扮演重要角色,多种GSK-3抑制剂在T2DM模型上表现出显著的抗糖尿病作用,作为治疗T2DM的新靶点正成为研究热门领域。本文就GSK-3的生物学特征、与T2DM的关系以及GSK-3抑制剂的最新研究进展做一综述。

Glycogen synthase kinase 3（GSK-3）is a multifunctional serine/threonine protein kinase expressed in various tissues and is involved in numerous cellular signal transduction pathways in vivo.Accumulating evidence implicated that dysregulation of GSK-3 plays an important role in the pathogenesis of type 2 diabetes mellitus（T2DM）.Here,we review recent progress in the researches on the biological characteristics of GSK-3,its relationship with T2DM and GSK-3 inhibitors as a novel target for antidiabetes.